Eli Lilly in our Pivotal Point Check: Weight Loss Pill Celebrates Study Success - Needle-Free Revolution for Weight Loss and Diabetes!
Reading Time: 3 minutes
Eli Lilly is the top beneficiary of needle-free alternatives in the booming weight loss and diabetes market. The release of study data for Orforglipron triggers a stock surge of 14%. Weight loss pill reduces body weight by an average of 7.9% after 40 weeks. On April 17, 2025, Eli Lilly announced that its obesity pill has met the targets in the first of several late-stage studies. With the oral GLP-1 drug, patients with type 2 diabetes can avoid injections without having to fear limitations in efficacy. The experimental pill, called...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
